SIA
ANIK icon

Stancorp Investment Advisers’s Anika Therapeutics ANIK Stock Holding History

Stancorp Investment Advisers’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$4K Hold
90
– – ﹤0.01% 551
2014
Q4 		$4K Buy
+90
New +$3.52K ﹤0.01% 545

Other funds holding ANIK

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LCP
Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Stancorp Investment Advisers's ANIK Position: Q1 2015 in Review

Stancorp Investment Advisers held its Anika Therapeutics (ANIK) position steady in Q1 2015 at 90 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #551.

Stancorp Investment Advisers first reported a position in ANIK in Q4 2014 and has held it in 2 quarters since. 159 funds tracked by Wall St. Rank hold ANIK as of Q1 2015.

  • Stancorp Investment Advisers held 90 shares of Anika Therapeutics worth $4K as of Q1 2015.
  • Stancorp Investment Advisers left its Anika Therapeutics share count unchanged in Q1 2015.
  • Anika Therapeutics made up ﹤0.01% of Stancorp Investment Advisers's portfolio in Q1 2015, its #551 holding.
  • Stancorp Investment Advisers first reported a position in Anika Therapeutics in Q4 2014 and has held it in 2 quarters since.
  • 159 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2015.

Based on Stancorp Investment Advisers's 13F filing for Q1 2015, filed 13 May 2015.